vir
An antiviral. A longer stem in front often says which virus or which viral enzyme it hits.
- Drugs containing vir: 108
- Approved somewhere: 46
- With a US drug page: 28
Approved and clinical-stage drugs in ChEMBL whose names containing vir or one of its sub-stems, matched by spelling; those with a US drug page link to it.
| Acts on | |||
|---|---|---|---|
| Oseltamivir | Approved | NA | Neuraminidase inhibitor |
| Zanamivir | Approved | NA | Neuraminidase inhibitor |
| Peramivir anhydrous | Approved | NA | Neuraminidase inhibitor |
| Laninamivir octanoate | Phase 3 | NA | Neuraminidase inhibitor |
| Laninamivir | Phase 2 | — | — |
| Daclatasvir | Approved | NS5A | Nonstructural protein 5A inhibitor |
| Elbasvir | Approved | NS5A | Nonstructural protein 5A inhibitor |
| Ledipasvir | Approved | NS5A | Nonstructural protein 5A inhibitor |
| Ombitasvir | Approved | NS5A | Nonstructural protein 5A inhibitor |
| Pibrentasvir | Approved | NS5A | Nonstructural protein 5A inhibitor |
| Velpatasvir | Approved | NS5A | Nonstructural protein 5A inhibitor |
| Yimitasvir | Phase 3 | — | — |
| Coblopasvir | Phase 2 | — | — |
| Odalasvir | Phase 2 | NS5A | Nonstructural protein 5A inhibitor |
| Ravidasvir | Phase 2 | NS5A | Nonstructural protein 5A inhibitor |
| Ruzasvir | Phase 2 | NS5A | Nonstructural protein 5A inhibitor |
| Samatasvir | Phase 2 | NS5A | Nonstructural protein 5A inhibitor |
| Sofosbuvir | Approved | NS5B | RNA-directed RNA polymerase inhibitor |
| Dasabuvir | Approved | NS5B | RNA-directed RNA polymerase inhibitor |
| Beclabuvir | Phase 3 | NS5B | RNA-directed RNA polymerase negative allosteric modulator |
| Bemnifosbuvir | Phase 3 | — | — |
| Deleobuvir | Phase 3 | NS5B | RNA-directed RNA polymerase inhibitor |
| Adafosbuvir | Phase 2 | NS5B | RNA-directed RNA polymerase inhibitor |
| Filibuvir | Phase 2 | NS5B | RNA-directed RNA polymerase inhibitor |
| Lomibuvir | Phase 2 | NS5B | RNA-directed RNA polymerase negative allosteric modulator |
| Nesbuvir | Phase 2 | NS5B | RNA-directed RNA polymerase inhibitor |
| Radalbuvir | Phase 2 | NS5B | RNA-directed RNA polymerase inhibitor |
| Setrobuvir | Phase 2 | NS5B | RNA-directed RNA polymerase inhibitor |
| Tegobuvir | Phase 2 | NS5B | RNA-directed RNA polymerase inhibitor |
| Uprifosbuvir | Phase 2 | NS5B | RNA-directed RNA polymerase inhibitor |
| Lenacapavir | Approved | GAG | Structural capsid protein inhibitor |
| Bersacapavir | Phase 2 | HBCAG | Core antigen modulator |
| Canocapavir | Phase 2 | — | — |
| Claficapavir | Phase 2 | — | — |
| Dezecapavir | Phase 2 | — | — |
| Suricapavir | Phase 2 | — | — |
| Zelicapavir | Phase 2 | — | — |
| Abacavir | Approved | POL | Human immunodeficiency virus type 1 reverse transcriptase inhibitor |
| Entecavir anhydrous | Approved | P | DNA polymerase/reverse transcriptase inhibitor |
| Abacavir hydroxyacetate | Phase 2 | — | — |
| Metacavir | Phase 2 | — | — |
| Famciclovir | Approved | DNA polymerase catalytic subunit | Human herpesvirus 1 DNA polymerase inhibitor |
| Penciclovir | Approved | DNA polymerase catalytic subunit | Human herpesvirus 1 DNA polymerase inhibitor |
| Valganciclovir | Approved | DNA polymerase catalytic subunit | Human herpesvirus 1 DNA polymerase inhibitor |
| Ganciclovir | Approved | DNA polymerase catalytic subunit | Human herpesvirus 1 DNA polymerase inhibitor |
| Valomaciclovir stearate | Phase 2 | — | — |
| Valomaciclovir | Phase 1 | — | — |
| Adefovir dipivoxil | Approved | P | DNA polymerase/reverse transcriptase inhibitor |
| Brincidofovir | Approved | OPG071 | DNA polymerase inhibitor |
| Tenofovir alafenamide | Approved | POL | Human immunodeficiency virus type 1 reverse transcriptase inhibitor |
| Tenofovir disoproxil | Approved | POL, P | Human immunodeficiency virus type 1 reverse transcriptase inhibitor |
| Cidofovir anhydrous | Approved | DNA polymerase catalytic subunit | Human herpesvirus 1 DNA polymerase inhibitor |
| Adefovir | Phase 3 | P | DNA polymerase/reverse transcriptase inhibitor |
| Besifovir | Phase 3 | — | — |
| Pradefovir | Phase 3 | P | DNA polymerase/reverse transcriptase inhibitor |
| Tenofovir anhydrous | Phase 3 | POL, P | Human immunodeficiency virus type 1 reverse transcriptase inhibitor |
| Rovafovir etalafenamide | Phase 2 | POL | Human immunodeficiency virus type 1 reverse transcriptase inhibitor |
| Tenofovir exalidex | Phase 2 | POL, REVERSE, TRANSCRIPTASE | Human immunodeficiency virus type 1 reverse transcriptase inhibitor |
| Celgosivir | Phase 2 | Alpha glucosidase | Alpha glucosidase inhibitor |
| Amprenavir | Approved | POL | Human immunodeficiency virus type 1 protease inhibitor |
| Atazanavir | Approved | POL | Human immunodeficiency virus type 1 protease inhibitor |
| Darunavir | Approved | POL | Human immunodeficiency virus type 1 protease inhibitor |
| Fosamprenavir | Approved | POL | Human immunodeficiency virus type 1 protease inhibitor |
| Nelfinavir | Approved | POL | Human immunodeficiency virus type 1 protease inhibitor |
| Ritonavir | Approved | POL, Cytochrome P450 3A | Human immunodeficiency virus type 1 protease inhibitor |
| Tipranavir | Approved | POL | Human immunodeficiency virus type 1 protease inhibitor |
| Indinavir anhydrous | Approved | POL | Human immunodeficiency virus type 1 protease inhibitor |
| Lopinavir | Approved | POL | Human immunodeficiency virus type 1 protease inhibitor |
| Saquinavir | Approved | POL | Human immunodeficiency virus type 1 protease inhibitor |
| Brecanavir | Phase 2 | POL | Human immunodeficiency virus type 1 protease inhibitor |
| Telinavir | Phase 1 | POL | Human immunodeficiency virus type 1 protease inhibitor |
| Boceprevir | Approved | NS3, NS4A | Hepatitis C virus serine protease, NS3/NS4A inhibitor |
| Simeprevir | Approved | NS3, NS4A | Hepatitis C virus serine protease, NS3/NS4A inhibitor |
| Telaprevir | Approved | NS3, NS4A | Hepatitis C virus serine protease, NS3/NS4A inhibitor |
| Asunaprevir | Approved | NS3, NS4A | Hepatitis C virus serine protease, NS3/NS4A inhibitor |
| Glecaprevir | Approved | NS3, NS4A | Hepatitis C virus serine protease, NS3/NS4A inhibitor |
| Grazoprevir anhydrous | Approved | NS3, NS4A | Hepatitis C virus serine protease, NS3/NS4A inhibitor |
| Paritaprevir | Approved | NS3, NS4A | Hepatitis C virus serine protease, NS3/NS4A inhibitor |
| Voxilaprevir | Approved | NS3, NS4A | Hepatitis C virus serine protease, NS3/NS4A inhibitor |
| Danoprevir | Phase 3 | NS3, NS4A | Hepatitis C virus serine protease, NS3/NS4A inhibitor |
| Faldaprevir | Phase 3 | NS3, NS4A | Hepatitis C virus serine protease, NS3/NS4A inhibitor |
| Furaprevir | Phase 3 | NS3, NS4A | Hepatitis C virus serine protease, NS3/NS4A inhibitor |
| Narlaprevir | Phase 3 | NS3, NS4A | Hepatitis C virus serine protease, NS3/NS4A inhibitor |
| Vaniprevir | Phase 3 | NS3, NS4A | Hepatitis C virus serine protease, NS3/NS4A inhibitor |
| Sovaprevir | Phase 2 | NS3, NS4A | Hepatitis C virus serine protease, NS3/NS4A inhibitor |
| Vedroprevir | Phase 2 | NS3, NS4A | Hepatitis C virus serine protease, NS3/NS4A inhibitor |
| Ciluprevir | — | NS3, NS4A | Hepatitis C virus serine protease, NS3/NS4A inhibitor |
| Doravirine | Approved | POL | Human immunodeficiency virus type 1 reverse transcriptase negative allosteric modulator |
| Etravirine | Approved | POL | Human immunodeficiency virus type 1 reverse transcriptase inhibitor |
| Rilpivirine | Approved | POL | Human immunodeficiency virus type 1 reverse transcriptase inhibitor |
| Dapivirine | Phase 3 | POL | Human immunodeficiency virus type 1 reverse transcriptase inhibitor |
| Bavtavirine | Phase 2 | — | — |
| Capravirine | Phase 2 | POL | Human immunodeficiency virus type 1 reverse transcriptase inhibitor |
| Depulfavirine | Phase 2 | — | — |
| Elsulfavirine | Phase 2 | — | — |
| Emivirine | Phase 2 | POL | Human immunodeficiency virus type 1 reverse transcriptase inhibitor |
| Lersivirine | Phase 2 | POL | Human immunodeficiency virus type 1 reverse transcriptase inhibitor |
| Ulonivirine | Phase 2 | — | — |
| Maraviroc | Approved | CCR5 | C-C chemokine receptor type 5 antagonist |
| Aplaviroc | Phase 3 | CCR5 | C-C chemokine receptor type 5 antagonist |
| Cenicriviroc | Phase 3 | CCR5, CCR2 | C-C chemokine receptor type 5 antagonist |
| Vicriviroc | Phase 3 | CCR5 | C-C chemokine receptor type 5 antagonist |
| Fomivirsen | Approved | Major intermediate early region 2 mRNA | Major intermediate early region 2 mRNA antisense inhibitor |
| Fomivirsen sodium | Phase 2 | Major intermediate early region 2 mRNA | Major intermediate early region 2 mRNA antisense inhibitor |
| Bepirovirsen | Phase 3 | mRNA | mRNA antisense inhibitor |
| Miravirsen | Phase 2 | microRNA 122 | microRNA 122 antisense inhibitor |
| Bepirovirsen sodium | Phase 1 | — | — |
| Radavirsen | Phase 1 | — | — |
Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO